To investigate the distribution of drug-resistant HIV-1 variants in plasma RNA and peripheral blood monuclear cell (PBMC) DNA at treatment failure while on therapy and after stopping therapy.
Design
Fifty-eight patients failing their first highly active antiretroviral treatment while on therapy and 50 patients after a median of 18.6 weeks after treatment interruption following multiple treatment failures were analysed.
Methods
Paired plasma HIV-1 RNA and PBMC HIV-1 DNA were used for genotypic antiretroviral resistance testing. Drug resistance was computed by using the Stanford on-line genotype interpretation system.
Results
The extent of drug resistance was larger in plasma RNA than in PBMC DNA in the on-therapy group (P=0.004) and in PBMC DNA than in plasma RNA in the off-therapy group (P=0.04). Interpretation of genotype based on PBMC DNA and plasma RNA in the on-therapy and in the off-therapy group would have missed detection of resistance to one or more drugs in 21 and 22% of the patients, respectively, compared to interpretation based on the other blood compartment. In a subset of 27 patients for whom a sample before stopping therapy was available, there was a significant decrease in the number of RNA (mean 8.1 to 5.3, P=0.004), but not DNA (mean 6.8 to 5.7, P=0.143), resistance mutations following treatment interruption.
Conclusion
While plasma RNA is the material of choice for early detection of drug resistance while on therapy, analysis of PBMC DNA may additionally support and possibly improve sensitivity of resistance testing in the absence of therapy.
References
1.
DevereuxH.L., YouleM., JohnsonM.A., & LovedayC.Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS1999; 13: F123–F127.
2.
VerhofstedeC., WanzeeleF.V., Van Der GuchtB., De CabooterN., & PlumJ.Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS1999; 13: 2541–2546.
3.
MillerV., SabinC., HertogsK., BloorS., Martinez-PicadoJ., D'AquilaR., LarderB., LutzT., GuteP., WeidmannE., RabenauH., PhillipsA., & StaszewskiS.Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS2000; 14: 2857–2867.
4.
IzopetJ., MassipP., SouyrisC., SandresK., PuissantB., ObadiaM., PasquierC., BonnetE., MarchouB., & PuelJ.Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS2000; 14: 2247–2255.
5.
DeeksS.G., WrinT., LieglerT., HohR., HaydenM., BarbourJ.D., HellmannN.S., PetropoulosC.J., McCuneJ.M., HellersteinM.K., & GrantR.M.Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. New England Journal of Medicine2001; 344: 472–480.
6.
ZazziM., RiccioM.L., VenturiG., CatucciM., RomanoL., De MilitoA., & ValensinP.E.Long-read direct infrared sequencing of crude PCR products for prediction of resistance to HIV-1 reverse transcriptase and protease inhibitors. Molecular Biotechnology1998; 10: 1–8.
SmithM.S., KoerberK.L., & PaganoJ.S.Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells. Journal of Infectious Diseases1993; 167: 445–448.
9.
KozalM.J., ShaferR.W., WintersM.A., KatzensteinD.A., & MeriganT.C.A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. Journal of Infectious Diseases1993; 167: 526–532.
10.
KayeS., ComberE., Tenant-FlowersM., & LovedayC.The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Research and Human Retroviruses1995; 11: 1221–1225.
11.
GunthardH.F., WongJ.K., IgnacioC.C., GuatelliJ.C., RiggsN.L., HavlirD.V., & RichmanD.D.Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. Journal of Virology1998; 72: 2422–2428.
12.
DevereuxH.L., LovedayC., YouleM., SabinC.A., BurkeA., & JohnsonM.Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. AIDS Research & Human Retroviruses2000; 16: 1025–1030.
13.
HanceA.J., LemialeV., IzopetJ., LecossierD., JolyV., MassipP., MammanoF., DescampsD., Brun-VezinetF., & ClavelF.Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. Journal of Virology2001; 75: 6410–6417.
14.
AlbrechtD., ZollnerB., FeuchtH.H., LorenzenT., LaufsR., StoehrA., & PlettenbergA.Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. Journal of Clinical Virology2002; 24: 93–98.
15.
DevereuxH.L., EmeryV.C., JohnsonM.A., & LovedayC.Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. Journal of Medical Virology2001; 65: 218–224.
16.
BirkM., SvedhemV., & SonnerborgA.Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. AIDS2001; 15: 1359–1368.
